Provider Briefing: Carbidopa-Levodopa Supply in 2026

Carbidopa-Levodopa remains the gold standard for pharmacologic management of Parkinson's disease, and your patients depend on uninterrupted access to this medication. Supply disruptions — particularly affecting extended-release and orally disintegrating formulations — continue to challenge both patients and prescribers in 2026.

This briefing provides a current overview of the supply landscape, prescribing considerations during periods of limited availability, and practical tools you can use to help patients maintain access.

Shortage Timeline and Current Status

Carbidopa-Levodopa supply disruptions are not new. Key milestones include:

• 2011–2015: Periodic shortages of both immediate-release and extended-release tablets reported to FDA and ASHP.
• 2020–2022: Pandemic-related supply chain disruptions affected generic manufacturing across the pharmaceutical industry, including Carbidopa-Levodopa.
• 2023–2024: Accord Healthcare discontinued Carbidopa-Levodopa 25/100 mg extended-release tablets. Sun Pharma discontinued its orally disintegrating tablet (ODT) formulation (25/100 mg).
• 2025–2026: Standard immediate-release tablets (10/100, 25/100, 25/250 mg) remain available from multiple generic manufacturers. Extended-release availability continues to be constrained, particularly for the 25/100 mg strength. The 50/200 mg ER tablet remains available from Accord and other manufacturers.

ASHP continues to track Carbidopa-Levodopa on its drug shortage database, and the FDA has issued updated labeling requirements including a new warning about Vitamin B6 (pyridoxine) deficiency and associated peripheral neuropathy or seizures with long-term use.

Prescribing Implications

During periods of constrained supply, consider the following:

Formulation Flexibility

If your patient's usual formulation is unavailable, the most straightforward adjustment is switching between formulations of Carbidopa-Levodopa itself:

• IR ↔ ER conversion: When converting from Sinemet CR (extended-release) to immediate-release, remember that bioavailability of the ER formulation is approximately 70–75% compared to IR. Total daily Levodopa dose may need to be increased by 25–30% when switching to ER, or decreased proportionally when switching to IR. Dosing intervals will also need adjustment (IR typically q4-6h vs. ER q6-8h).
• Rytary: This extended-release capsule has a unique pharmacokinetic profile with both immediate and sustained release components. Conversion from IR Carbidopa-Levodopa requires using the manufacturer's dosing table. Rytary is generally available but at significantly higher cost ($700–$1,500+/month).
• Crexont: A newer extended-release capsule option that may offer improved drug-level consistency. Can serve as an alternative when generic ER tablets are unavailable.
• Stalevo (Carbidopa-Levodopa-Entacapone): May be appropriate for patients who need extended "on" time and whose ER formulation is unavailable. Entacapone inhibits COMT, prolonging Levodopa's action.

Therapeutic Alternatives

For patients who cannot access any Carbidopa-Levodopa formulation, consider:

• Dopamine agonists (Pramipexole, Ropinirole, Rotigotine): Reasonable first-line alternatives for early-stage disease. Less effective than Carbidopa-Levodopa for moderate-to-advanced motor symptoms. Monitor for impulse control disorders, somnolence, and orthostatic hypotension.
• MAO-B inhibitors (Rasagiline, Selegiline, Safinamide): Useful as monotherapy in early disease or as adjuncts. Mild symptomatic benefit. Note drug-drug interaction profile, particularly with antidepressants.
• Amantadine: Limited efficacy as monotherapy but valuable for Levodopa-induced dyskinesia management. Extended-release formulation (Gocovri) is FDA-approved specifically for this indication.

For a patient-facing version of these alternatives, you may direct patients to our article on alternatives to Carbidopa.

The Availability Picture: What's In Stock

Supply varies by region, but the general landscape in 2026:

• Widely available: Generic IR tablets (all strengths) from Mylan/Viatris, Teva, Aurobindo, and others.
• Constrained: Generic ER tablets (especially 25/100 mg), ODT formulations.
• Available at higher cost: Rytary, Crexont, Duopa (specialty pharmacy distribution).

Cost and Access Considerations

Generic Carbidopa-Levodopa remains affordable for most patients:

• Generic IR with coupon: $9–$24 for 90 tablets
• Generic IR without insurance: $30–$85 for 90 tablets
• Generic ER with coupon: $15–$40 for 90 tablets

For patients facing financial barriers, discount programs (SingleCare, GoodRx) and patient assistance resources (Parkinson's Foundation, NeedyMeds, RxAssist) can help. We've compiled a patient-facing resource: How to save money on Carbidopa.

The "eight Sinemet limit" — where pharmacies or PBMs restrict dispensing to ≤8 tablets/day — can be a barrier for patients on higher doses. If your patient requires more than 8 tablets daily, proactive documentation and prior authorization requests may be necessary.

Tools and Resources for Providers

• Medfinder for Providers: Search real-time pharmacy stock to help patients locate their specific Carbidopa-Levodopa formulation and strength near them.
• ASHP Drug Shortage Database: Monitor current shortage status and expected resolution timelines.
• FDA Drug Shortages page: Check for manufacturer communications and expected supply dates.
• Parkinson's Foundation (1-800-4PD-INFO): Patient navigation services, including medication access support.

For a step-by-step workflow on helping patients with stock-outs, see our provider guide: How to help your patients find Carbidopa in stock.

Looking Ahead

Several developments may improve the supply landscape for Carbidopa-Levodopa:

• New formulations (Crexont, Dhivy) adding manufacturing capacity and distribution channels.
• FDA oversight: Increased scrutiny of generic drug supply chains and manufacturing quality may help prevent future disruptions.
• Telehealth expansion: Virtual visits allow faster prescription adjustments during supply disruptions, reducing the time patients go without medication.

Final Thoughts

Carbidopa-Levodopa supply disruptions are a recurring challenge for Parkinson's disease management. By maintaining formulation flexibility in your prescribing approach, leveraging real-time stock-checking tools like Medfinder for Providers, and proactively communicating with patients about backup plans, you can minimize the impact of shortages on your patients' care.

For additional provider resources, including a guide on helping patients save on this medication, see How to help patients save money on Carbidopa: A provider's guide.